The Path I Traversed: From Kammankattukalam to Kalam "I never imagined that the hands that once held the plow would one day shake hands with Dr. Kalam. During those days, though life was rooted in toil, I never let go of hope or self-confidence. It was this unwavering belief that turned even unimagined dreams into reality. From humble beginnings to extraordinary moments, my journey stands as a testament to resilience and the power of dreams fueled by determination and self-trust."
Saturday, August 29, 2026
Friday, August 28, 2026
Thursday, August 27, 2026
25000 Citations 167 Publications - A career milestone
Viewed across more than three decades, the most meaningful feature of my scientific career is not simply its publication count or the milestone of 25,000 citations, but the continuity of a scientific question pursued through successive generations of technology. My early work was grounded in cytogenetics and the analysis of chromosomal abnormalities. As molecular and genomic technologies developed, that interest evolved naturally toward identifying the genes affected by recurrent rearrangements, understanding the biological consequences of gene fusions, and determining how structural genomic alterations define molecular subsets of human cancer.
Prostate cancer ultimately became the principal setting in which these interests converged. My work contributed to studies spanning recurrent ETS-family alterations, PTEN-associated genomic changes, transcriptome-based gene-fusion discovery, RAF and other kinase rearrangements, molecular heterogeneity, biomarkers, and the genomic landscape of advanced and treatment-resistant prostate cancer. Collectively, these studies helped advance a view of prostate cancer not as a single molecular disease, but as a collection of biologically distinct subsets defined by recurrent genomic and transcriptional alterations.
The citation record provides one quantitative measure of the reach of this work. More than 25,000 citations have accumulated across the publication portfolio. Importantly, this influence is not attributable to a single publication. Several papers have received more than 1,000 citations; the top ten account for approximately 41% of the total, and nearly 43% of all citations arise from publications outside the top twenty. This distribution indicates both landmark contributions and substantial breadth of influence across the larger body of work.
Equally important is the duration of that influence. Highly cited publications span work from chromosome biology and cancer cytogenetics in the 1990s through gene-fusion and cancer-genomics discoveries of the following decades and into contemporary studies of prostate cancer heterogeneity, tumor evolution, molecular biomarkers, and therapeutic vulnerabilities. The scientific tools have changed—from chromosome analysis and FISH to transcriptome sequencing, next-generation genomics, molecular pathology and spatial approaches—but the underlying objective has remained remarkably consistent: to identify genomic alterations that reveal how cancers arise, evolve and behave.
The translational dimension of this work is particularly meaningful to me. Discovering an alteration is only the beginning. The larger objective is to determine whether it can improve molecular classification, diagnosis, prognostication or therapeutic selection. Work on gene fusions, kinase rearrangements, ERG/PTEN biology, molecular detection methods and experimentally tractable prostate cancer models represents different stages of that continuum from genomic observation to biological and potentially clinical significance.
At this stage of my career, I therefore regard 25,000 citations less as a destination than as evidence that a substantial portion of the work has entered the intellectual foundation of subsequent research. Citations cannot by themselves measure originality, individual contribution or clinical importance, and they should not be treated as a ranking of scientific worth. Their significance here lies in their breadth and persistence: discoveries made at different stages of the career have continued to be used, tested and extended by other investigators.
Perhaps the most satisfying perspective is that the career has paralleled—and contributed to—a fundamental transformation in cancer genetics. The field progressed from observing abnormal chromosomes to identifying their molecular consequences, sequencing entire cancer genomes and transcriptomes, defining molecular subtypes, and increasingly resolving tumor heterogeneity at cellular and spatial resolution. My own scientific trajectory has followed that same arc.
The next phase should therefore not simply seek to add publications or citations to an established record. Its value will depend on using the accumulated experience in cancer cytogenetics, structural genomics, and prostate cancer biology to address questions that remain unresolved: how molecularly distinct prostate cancers evolve over time, how treatment reshapes their genomes and phenotypes, how tumor heterogeneity produces resistance, and which genomic alterations represent genuine therapeutic vulnerabilities.
Ultimately, the most durable measure of a scientific career is not the number of papers published or citations accumulated. It is whether some of its observations became useful to other scientists—whether they changed a question, enabled an experiment, helped define a disease mechanism, or provided a foundation on which subsequent discoveries could be built. By that standard, the 25,000-citation milestone is meaningful primarily because it reflects the work's cumulative scientific life beyond the laboratory where it originated.
Wednesday, August 26, 2026
Subscribe to:
Posts (Atom)
